Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease

Amin Alirezaylavasani¹, Ingrid Marie Egner¹, Børresdatter Dahl², Adity Chopra³, Taissa de Matos Kasahara⁴, Guro Løvik Goll⁵, Jørgen Jahnsen⁶, Gunnveig Grødeland⁷, John Torgils Vaage⁷, Fridtjof Lund-Johansen³, Jan Cato Holter⁸, Bente Halvorsen⁹, Kristin Kaasen Jørgensen¹⁰, Ludvig A Munthe¹¹, Hassen Kared¹²

Affiliations

¹ Department of Immunology, Oslo University Hospital, Oslo, Norway; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Norway; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.
² Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.
³ Department of Immunology, Oslo University Hospital, Oslo, Norway; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway; ImmunoLingo Convergence Center, University of Oslo, Oslo, Norway.
⁴ Department of Immunology, Oslo University Hospital, Oslo, Norway.
⁵ Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway; Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo, Norway.
⁶ Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
⁷ Department of Immunology, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
⁸ Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Microbiology, Oslo University Hospital, Oslo, Norway.
⁹ Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
¹⁰ Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway.
¹¹ Department of Immunology, Oslo University Hospital, Oslo, Norway; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Norway; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway. Electronic address: l.a.munthe@medisin.uio.no.
¹² Department of Immunology, Oslo University Hospital, Oslo, Norway; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Norway; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway. Electronic address: hassen.kared@medisin.uio.no.

PMID: 39645159
DOI: 10.1016/j.clim.2024.110404

Free article

Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease

Amin Alirezaylavasani et al. Clin Immunol. 2025 Feb.

Free article

. 2025 Feb:271:110404.

doi: 10.1016/j.clim.2024.110404. Epub 2024 Dec 5.

Authors

Affiliations

¹ Department of Immunology, Oslo University Hospital, Oslo, Norway; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Norway; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.
² Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.
³ Department of Immunology, Oslo University Hospital, Oslo, Norway; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway; ImmunoLingo Convergence Center, University of Oslo, Oslo, Norway.
⁴ Department of Immunology, Oslo University Hospital, Oslo, Norway.
⁵ Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway; Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo, Norway.
⁶ Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
⁷ Department of Immunology, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
⁸ Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Microbiology, Oslo University Hospital, Oslo, Norway.
⁹ Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
¹⁰ Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway.
¹¹ Department of Immunology, Oslo University Hospital, Oslo, Norway; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Norway; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway. Electronic address: l.a.munthe@medisin.uio.no.
¹² Department of Immunology, Oslo University Hospital, Oslo, Norway; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Norway; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway. Electronic address: hassen.kared@medisin.uio.no.

PMID: 39645159
DOI: 10.1016/j.clim.2024.110404

Abstract

Patients with Inflammatory Bowel Disease (IBD) undergoing immunosuppressive therapies face heightened susceptibility to severe COVID-19. An in-depth understanding of systemic inflammation and cellular immune responses after SARS-CoV-2 vaccination and breakthrough infections (BTI) is required for optimizing vaccine strategies in this population. While the prevalence of high serological responders post- third COVID-19 vaccine dose was lower, and the antibody waning was higher in IBD patients than in healthy donors (HD), IBD patients showed an increase in anti-RBD Wild Type IgG levels and cross-reactive Spike -specific memory B cells following BTI. However, there was no significant enhancement in cellular immune responses against anti-SARS-CoV-2 post-BTI, with responses instead characterized by activation of SARS-CoV-2 specific and also bystander CD8 T cells. These results suggest a complex interaction between chronic inflammation in IBD and the generation of new immune responses, highlighting the need for tailored vaccine regimens and anti-inflammatory therapies to boost cellular immunity against SARS-CoV-2.

Keywords: Activation; Antibody waning; Hybrid immunity; IBD; Inflammation; TNF inhibitors.

PubMed Disclaimer

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease

Affiliations

Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease

Authors

Affiliations

Abstract

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous